

Alice Y Cheng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8487929/publications.pdf>

Version: 2024-02-01

52
papers

2,365
citations

394286

19
h-index

223716

46
g-index

54
all docs

54
docs citations

54
times ranked

3132
citing authors

#	ARTICLE	IF	CITATIONS
1	Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists. <i>Stroke</i> , 2022, 53, 1813-1822.	1.0	18
2	Therapieintensivierung bei mit basalunterstützter oraler Therapie (BOT) unkontrolliertem Typ-2-Diabetes: Subanalyse der SoliMix-Studie bei Teilnehmern in Europa. <i>Diabetologie Und Stoffwechsel</i> , 2022, , .	0.0	0
3	Therapieintensivierung bei mit basalunterstützter oraler Therapie (BOT) unkontrolliertem Typ-2-Diabetes: NÄchtliche Hypoglykämien in der SoliMix-Studie. <i>Diabetologie Und Stoffwechsel</i> , 2022, , .	0.0	0
4	Therapieintensivierung bei Typ-2-Diabetespatienten mit basalunterstützter oraler Therapie (BOT): Hypoglykämien als Funktion des HbA1c in der SoliMix-Studie. <i>Diabetologie Und Stoffwechsel</i> , 2022, , .	0.0	0
5	Assessing the Effect of Quality-Improvement Strategies for Organization of Care in Type 2 Diabetes Outcomes in Adults: Aim-Strait. <i>Canadian Journal of Diabetes</i> , 2021, 45, 319-326.e5.	0.4	3
6	Why Choose Between SGLT2 Inhibitors and GLP1-RA When You Can Use Both?. <i>Circulation</i> , 2021, 143, 780-782.	1.6	10
7	Glycemic Control and Cardiovascular Risk Factor Management in Adults With Type 2 Diabetes With and Without Chronic Kidney Disease Before Sodium-Glucose Cotransporter Protein 2 Inhibitors: Insights From the Diabetes Mellitus Status in Canada Survey. <i>Canadian Journal of Diabetes</i> , 2021, , .	0.4	1
8	Glycaemic control and hypoglycaemia risk with insulin glargine 300â€‰%U/mL and insulin degludec 100â€‰%U/mL in older participants in the BRIGHT trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1588-1593.	2.2	7
9	SGLT-2 inhibitors: does it matter if they prevent type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, , .	5.5	0
10	Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 346-354.	2.2	6
11	The Safety and Efficacy of Second-Generation Basal Insulin Analogues in Adults with Type 2 Diabetes at Risk of Hypoglycemia and Use in Other Special Populations: A Narrative Review. <i>Diabetes Therapy</i> , 2020, 11, 2555-2593.	1.2	16
12	Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 418-435.	5.5	105
13	Differential glycaemic control with basal insulin glargine 300 <sc>U/mL</sc> versus degludec 100 <sc>U/mL</sc> according to kidney function in type 2 diabetes: A subanalysis from the <sc>BRIGHT</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1369-1377.	2.2	26
14	Insulin glargine 300â€‰%U/<sc>mL</sc> and insulin degludec: A review of the current evidence comparing these two secondâ€‰generation basal insulin analogues. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3329.	1.7	12
15	Time to Rethink Reducing Cardiovascular Risk: Are We Ready?. <i>Canadian Journal of Diabetes</i> , 2020, 44, 1-3.	0.4	2
16	Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different. <i>Advances in Therapy</i> , 2019, 36, 1018-1030.	1.3	33
17	Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement. <i>Canadian Journal of Diabetes</i> , 2019, 43, 384-391.	0.4	11
18	Insulin Matters: A Practical Approach to Basal Insulin Management in Type 2 Diabetes. <i>Diabetes Therapy</i> , 2018, 9, 501-519.	1.2	18

#	ARTICLE	IF	CITATIONS
19	Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important?. Diabetes Research and Clinical Practice, 2018, 142, 19-25.	1.1	16
20	Insights Into the Current Management of Older Adults With Type 2 Diabetes in the Ontario Primary Care Setting. Canadian Journal of Diabetes, 2018, 42, 23-30.	0.4	16
21	Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey. Canadian Journal of Diabetes, 2018, 42, 130-137.	0.4	25
22	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. Cmaj, 2018, 190, E1192-E1206.	0.9	39
23	CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management. Canadian Journal of Cardiology, 2018, 34, 1350-1361.	0.8	4
24	More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial. Diabetes Care, 2018, 41, 2147-2154.	4.3	159
25	A Practical Guide to the Use of Glucose-Lowering Agents With Cardiovascular Benefit or Proven Safety. Canadian Journal of Cardiology, 2017, 33, 940-942.	0.8	5
26	So Many Antihyperglycemics: How to Choose? A Practical Approach. Canadian Journal of Diabetes, 2017, 41, 469-473.	0.4	3
27	Diabetes for Cardiologists: Practical Issues in Diagnosis and Management. Canadian Journal of Cardiology, 2017, 33, 366-377.	0.8	25
28	SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis. Clinical Therapeutics, 2016, 38, 2654-2664.e1.	1.1	197
29	Optimizing the language and format of guidelines to improve guideline uptake. Cmaj, 2016, 188, E362-E368.	0.9	51
30	Glycaemic control and cardiovascular risk factor management in patients with diabetes with and without coronary artery disease: insights from the diabetes mellitus status in Canada survey. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 2, 277-284.	1.8	14
31	Policies, Guidelines and Consensus Statements: Pharmacologic Management of Type 2 Diabetes—2015 Interim Update. Canadian Journal of Diabetes, 2015, 39, 250-252.	0.4	33
32	Diabetes and Driving: 2015 Canadian Diabetes Association Updated Recommendations for Private and Commercial Drivers. Canadian Journal of Diabetes, 2015, 39, 347-353.	0.4	7
33	Breaking down barriers to initiating insulin: Insulin prescription pad. Canadian Family Physician, 2015, 61, 445-7.	0.1	3
34	Frontline over ivory tower: key competencies in community-based curricula. Canadian Medical Education Journal, 2015, 6, e34-42.	0.3	0
35	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE): 2014 update. Cmaj, 2014, 186, 1299-1305.	0.9	19
36	In-Hospital Diabetes Management. Canadian Journal of Diabetes, 2014, 38, 71-72.	0.4	3

#	ARTICLE	IF	CITATIONS
37	Achieving Glycemic Control in Special Populations in Hospital: Perspectives in Practice. Canadian Journal of Diabetes, 2014, 38, 134-138.	0.4	8
38	Dual Reporting of Hemoglobin A1C in the Canadian Journal of Diabetes. Canadian Journal of Diabetes, 2014, 38, 161-163.	0.4	0
39	Type 2 Diabetes Mellitus Management in Canada: Is It Improving?. Canadian Journal of Diabetes, 2013, 37, 82-89.	0.4	127
40	Methods. Canadian Journal of Diabetes, 2013, 37, S4-S7.	0.4	318
41	The Canadian Diabetes Association 2013 Clinical Practice Guidelinesâ€”Raising the Bar and Setting Higher Standards!. Canadian Journal of Diabetes, 2013, 37, 137-138.	0.4	57
42	Introduction. Canadian Journal of Diabetes, 2013, 37, S1-S3.	0.4	447
43	Time perspective and weight management behaviors in newly diagnosed Type 2 diabetes: a mediational analysis. Journal of Behavioral Medicine, 2012, 35, 569-580.	1.1	43
44	Glucose lowering and cardiovascular disease: what do we know and what should we do?. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, s25-s31.	3.1	12
45	Cardiovascular risk and glycemic control. Cmaj, 2009, 180, 907-908.	0.9	4
46	Diabetes and cardiovascular disease: The role of glycemic control. Current Diabetes Reports, 2009, 9, 65-72.	1.7	10
47	PPAR-alpha: therapeutic role in diabetes-related cardiovascular disease. Diabetes, Obesity and Metabolism, 2008, 10, 691-698.	2.2	21
48	Oral antihyperglycemic therapy for type 2 diabetes mellitus. Cmaj, 2005, 172, 213-226.	0.9	354
49	Does tighter perioperative glycemic control improve outcomes for diabetic patients undergoing coronary artery bypass graft surgery?. Cmaj, 2004, 171, 30-31.	0.9	1
50	Thiazolidinedione-Induced Congestive Heart Failure. Annals of Pharmacotherapy, 2004, 38, 817-820.	0.9	45
51	Tumefactive Fibroinflammatory Lesion of the Nasal Cavity Followed by Riedel's Thyroiditis. The Journal of Otolaryngology, 2004, 33, 315.	0.6	7
52	Developing a quality of life measure for Chinese patients with diabetes. Diabetes Research and Clinical Practice, 1999, 46, 259-267.	1.1	24